Breakthrough in TNBC Treatment with Carboplatin
A study led by Tata Memorial Centre reveals that the addition of low-cost chemotherapy drug carboplatin to standard treatment improves cure and survival rates for patients under 50 with triple-negative breast cancer (TNBC). The trial discovered significant benefits for younger women, offering a promising treatment option worldwide.
- Country:
- India
A recent study conducted by Tata Memorial Centre has shown promising results in the treatment of triple-negative breast cancer (TNBC), particularly in women under the age of 50. The study highlights the addition of carboplatin, a low-cost chemotherapy drug, to standard treatment regimens.
The randomised Phase III trial included 720 women with stage II-III TNBC who had not seen their cancer spread beyond axillary lymph nodes. Conducted at the Tata Memorial Centre in Mumbai between 2010 and 2020, the trial compared standard chemotherapy regimens with an additional weekly dose of carboplatin.
The study found that the inclusion of carboplatin did not cause significant side effects, thereby making it a viable addition to treatment plans. Experts anticipate that this new approach will be widely adopted, especially in countries with a higher prevalence of younger patients, offering an affordable yet effective option.
Google News